# Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 750mg and Rosuvastatin 20mg

> **NCT01929512** · PHASE1 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 72 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** HCP1201 750/20mg
- **DRUG:** Metformin SR 750mg
- **DRUG:** Rosuvastatin 20mg

## Key facts

- **NCT ID:** NCT01929512
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2013-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01929512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01929512, "Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 750mg and Rosuvastatin 20mg". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01929512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*